Form 8-K · Current report
Cencora 8-K, filed Nov 4, 2026
- Filed
- CIK
- 0001140859
- Accession no.
- 0001140859-26-000040
Summary
Cencora completed a restructuring of its operating model and will begin reporting under a new structure in the first quarter of fiscal 2027, with segments Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other, the latter holding businesses under strategic review including MWI Animal Health, Profarma, and other components of PharmaLex. Cencora also provided revised unaudited segment revenue and operating income information for fiscal 2026 and 2025 under the new structure.
Key points
- The new Pharmaceutical Distribution and Services segment will cover U.S. and international wholesale pharmaceutical distribution and related services for health systems, retail pharmacies, and alternate sites of care.
- The Specialty Pharmaceutical and Provider Services segment will include specialty distribution to physician practices, management services organizations, World Courier and 3PL services, Innomar, and strategic components of PharmaLex.
- Other, which is not a reportable segment, includes MWI Animal Health, Profarma, and other PharmaLex components, for which Cencora is exploring strategic alternatives.
- Revised unaudited segment data for fiscal 2026 and 2025 was provided under the new reporting structure.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 7.01Regulation FD Disclosure
- 9.01Financial Statements and Exhibits
From the filing
Item 7.01. Regulation FD Disclosure. New Reporting Structure In order to advance its growth priorities, Cencora recently completed a restructuring of its operating model intended to strengthen execution and improve visibility. As a result of this restructuring, the Company has reorganized all business components within the U.S. Healthcare Solutions and International Healthcare Solutions reportable segments. Beginning in the first quarter of fiscal 2027, the Company’s reporting structure will be comprised of Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. The Pharmaceutical Distribution and Services reportable segment will consist of U.S. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.